Global Cancer Drugs Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Drug Class;

Cytotoxic Drugs, Targeted Drugs, Hormonal Drugs, and Others.

By Indication;

Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, and Others.

By Therapy;

Immunotherapy, Targeted Therapy, Chemotherapy, Hormone Therapy, and Others.

By Cancer Type;

Breast Cancer, Blood Cancer, Gastrointestinal Cancer, Prostate Cancer, Skin Cancer, Lung Cancer, and Others.

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn846064677 Published Date: April, 2025 Updated Date: May, 2025

Introduction

Global Cancer Drugs Market (USD Million), 2021 - 2031

In the year 2024, the Global Cancer Drugs Market was valued at USD 180,948.28 million. The size of this market is expected to increase to USD 300,202.09 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7.5%.


Global Cancer Drugs Market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 7.5 %


Study Period2025 - 2031
Base Year2024
CAGR (%)7.5 %
Market Size (2024)USD 180,948.28 Million
Market Size (2031)USD 300,202.09 Million
Market ConcentrationMedium
Report Pages378
180,948.28
2024
300,202.09
2031

Major Players

  • Roche
  • Merck & Co., Inc.
  • Novartis
  • Bristol-Myers Squibb
  • Pfizer
  • AstraZeneca
  • Johnson & Johnson
  • Takeda Pharmaceutical Company
  • AbbVie
  • Eli Lilly and Company

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global Cancer Drugs Market

Fragmented - Highly competitive market without dominant players


The Global Cancer Drugs Market is expanding rapidly, driven by the rising prevalence of cancer and the growing emphasis on advanced treatment options. As cancer becomes more prevalent among chronic diseases, pharmacological therapies are playing a critical role in patient management. More than 50% of individuals receiving cancer treatment now rely on drug therapies, underscoring their importance in clinical care.

Growing Preference for Targeted Treatment Approaches
The industry is shifting toward targeted and precision therapies that offer better outcomes with minimized side effects. Drugs such as monoclonal antibodies and tyrosine kinase inhibitors have gained prominence, making up about 45% of cancer drug utilization. This trend is redefining treatment strategies and facilitating more individualized therapeutic responses.

Rising Popularity of Immune-Based Therapies
Immunotherapies are gaining widespread acceptance for their ability to activate the immune system in targeting cancer cells. Currently, they account for over 30% of drug use in oncology, reflecting a major transformation in treatment approaches. From checkpoint inhibitors to adoptive cell therapies, these drugs are reshaping cancer care protocols.

Healthcare Incentives Enabling Broader Access
Government-led healthcare incentives and insurance coverage policies are making cancer drugs more accessible to the public. Around 35% of cancer-related public programs now offer reimbursement for pharmacological treatments, improving affordability and patient adherence. These developments are crucial in ensuring equitable access to advanced cancer care.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Drug Class
    2. Market Snapshot, By Indication
    3. Market Snapshot, By Therapy
    4. Market Snapshot, By Cancer Type
    5. Market Snapshot, By Region
  4. Global Cancer Drugs Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Research and development advancements
        2. Increasing cancer prevalence
        3. Technological innovations in drug delivery
      2. Restraints
        1. High cost of cancer drugs
        2. Stringent regulatory requirements
        3. Side effects associated with treatments
      3. Opportunities
        1. Personalized medicine approaches
        2. Emerging markets in Asia-Pacific and Latin America
        3. Development of targeted therapies
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Industry Rivalry
  5. Market Segmentation
    1. Global Cancer Drugs Market, By Drug Class, 2021 - 2031 (USD Million)
      1. Cytotoxic Drugs
      2. Targeted Drugs
      3. Hormonal Drugs
      4. Others.
    2. Global Cancer Drugs Market, By Indication, 2021 - 2031 (USD Million)
      1. Lung Cancer
      2. Stomach Cancer
      3. Colorectal Cancer
      4. Breast Cancer
      5. Prostate Cancer
      6. Others
    3. Global Cancer Drugs Market, By Therapy, 2021 - 2031 (USD Million)
      1. Immunotherapy
      2. Targeted Therapy
      3. Chemotherapy
      4. Hormone Therapy
      5. Others
    4. Global Cancer Drugs Market, By Cancer Type, 2021 - 2031 (USD Million)
      1. Breast Cancer
      2. Blood Cancer
      3. Gastrointestinal Cancer
      4. Prostate Cancer
      5. Skin Cancer
      6. Lung Cancer
      7. Others
    5. Global Cancer Drugs Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Roche
      2. Merck & Co. Inc.
      3. Novartis
      4. Bristol-Myers Squibb
      5. Pfizer
      6. AstraZeneca
      7. Johnson & Johnson
      8. Takeda Pharmaceutical Company
      9. AbbVie
      10. Eli Lilly and Company
  7. Analyst Views
  8. Future Outlook of the Market